

Giovanni Barbara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2272251/publications.pdf>

Version: 2024-02-01

129
papers

13,694
citations

31902

53
h-index

21474

114
g-index

153
all docs

153
docs citations

153
times ranked

10711
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. <i>Gastroenterology</i> , 2004, 126, 693-702.	0.6	1,246
2	Intestinal permeability "a new target for disease prevention and therapy. <i>BMC Gastroenterology</i> , 2014, 14, 189.	0.8	1,187
3	Intestinal microbiota in functional bowel disorders: a Rome foundation report. <i>Gut</i> , 2013, 62, 159-176.	6.1	776
4	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16014.	18.1	674
5	Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2007, 132, 26-37.	0.6	668
6	Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. <i>Gastroenterology</i> , 1996, 110, 1036-1042.	0.6	602
7	Role for protease activity in visceral pain in irritable bowel syndrome. <i>Journal of Clinical Investigation</i> , 2007, 117, 636-647.	3.9	490
8	Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. <i>Gut</i> , 2009, 58, 196-201.	6.1	438
9	Methodology and Indications of H ₂ Breath Testing in Gastrointestinal Diseases: the Rome Consensus Conference. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1-49.	1.9	320
10	Activation of Human Enteric Neurons by Supernatants of Colonic Biopsy Specimens From Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2009, 137, 1425-1434.	0.6	304
11	Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms. <i>American Journal of Gastroenterology</i> , 2009, 104, 392-400.	0.2	301
12	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 2560-2568.	0.2	291
13	The Intestinal Microenvironment and Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1305-1318.e8.	0.6	243
14	A role for inflammation in irritable bowel syndrome?. <i>Gut</i> , 2002, 51, i41-i44.	6.1	212
15	Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. <i>Gastroenterology</i> , 1997, 113, 1224-1232.	0.6	185
16	Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 1290-1298.	0.2	179
17	Natural History of Chronic Idiopathic Intestinal Pseudo-Obstruction in Adults: A Single Center Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 449-458.	2.4	176
18	The Immune System in Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 349-359.	0.8	171

#	ARTICLE	IF	CITATIONS
19	Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11653-11658.	3.3	165
20	New pathophysiological mechanisms in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2004, 20, 1-9.	1.9	165
21	Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology, 2019, 156, 46-58.e7.	0.6	162
22	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterology and Motility, 2007, 19, 440-452.	1.6	158
23	Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterology and Motility, 2006, 18, 6-17.	1.6	154
24	Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal, 2014, 2, 413-442.	1.6	141
25	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut, 2017, 66, 1252-1261.	6.1	138
26	European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. Colorectal Disease, 2020, 22, 5-28.	0.7	132
27	Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Alimentary Pharmacology and Therapeutics, 2009, 30, 245-252.	1.9	127
28	Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 148, 1002-1011.e4.	0.6	127
29	Loss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel Syndrome. Gastroenterology, 2014, 146, 1659-1668.	0.6	120
30	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	6.1	120
31	Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterology and Motility, 2018, 30, e13192.	1.6	119
32	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 149, 433-444.e7.	0.6	116
33	Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome. Current Gastroenterology Reports, 2011, 13, 308-315.	1.1	109
34	Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers. FEMS Microbiology Ecology, 2016, 92, fiw191.	1.3	102
35	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Frontiers in Nutrition, 2021, 8, 718356.	1.6	98
36	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	6.1	97

#	ARTICLE	IF	CITATIONS
37	Pre- and probiotic overview. <i>Current Opinion in Pharmacology</i> , 2018, 43, 87-92.	1.7	97
38	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016, 65, 82-90.	6.1	91
39	Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. <i>Gastroenterology</i> , 2001, 120, 1729-1736.	0.6	85
40	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 909-922.	1.9	81
41	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017, 5, 773-788.	1.6	81
42	Salmonella Gastroenteritis During Childhood Is a Risk Factor for Irritable Bowel Syndrome in Adulthood. <i>Gastroenterology</i> , 2014, 147, 69-77.	0.6	77
43	Effect of <i>Lactobacillus paracasei</i> CNCM 1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. <i>United European Gastroenterology Journal</i> , 2018, 6, 604-613.	1.6	77
44	Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction. <i>Gastroenterology</i> , 2015, 148, 771-782.e11.	0.6	71
45	Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, S52-S55.	1.1	67
46	Treatment of Diverticular Disease of the Colon and Prevention of Acute Diverticulitis: A Systematic Review. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1326-1338.	0.7	65
47	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1673-1676.	2.4	64
48	Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1118.	1.6	62
49	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	1.6	62
50	Postinfectious Irritable Bowel Syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, S95-7.	0.9	60
51	Fecal Clostridiales distribution and short chain fatty acids reflect bowel habits in irritable bowel syndrome. <i>Environmental Microbiology</i> , 2018, 20, 3201-3213.	1.8	59
52	Novel therapeutic targets for enteric nervous system disorders. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 473-481.	4.0	55
53	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 168-179.	0.6	55
54	Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. <i>Neurogastroenterology and Motility</i> , 2014, 26, 196-204.	1.6	54

#	ARTICLE	IF	CITATIONS
55	Inflammatory bowel disease and irritable bowel syndrome. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 352-358.	1.0	53
56	Managing the Inevitable Surge of Post-“COVID-19 Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2021, 116, 4-7.	0.2	51
57	Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after <i>Salmonella</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1127-1131.	1.9	49
58	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. <i>Gut</i> , 2020, 69, 1966-1974.	6.1	49
59	Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2011, 23, 1084-1091.	1.6	48
60	Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1147-1155.	1.7	46
61	Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1134.	1.6	45
62	Implications of SARS-CoV-2 infection for neurogastroenterology. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14104.	1.6	45
63	Stress, Inflammation and the Irritable Bowel Syndrome. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999, 13, 47A-49A.	1.8	44
64	Natural History of Intestinal Failure Induced by Chronic Idiopathic Intestinal Pseudo-Obstruction. <i>Transplantation Proceedings</i> , 2010, 42, 15-18.	0.3	44
65	5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D. <i>Science Signaling</i> , 2018, 11, .	1.6	44
66	Interferon- β is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G439-G447.	1.6	40
67	Recent advances in understanding non-celiac gluten sensitivity. <i>F1000Research</i> , 2018, 7, 1631.	0.8	40
68	Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey. <i>United European Gastroenterology Journal</i> , 2018, 6, 1245-1253.	1.6	40
69	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 147-157.	0.2	39
70	Unsuccessful Octreotide Treatment of the Watermelon Stomach. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 345-346.	1.1	37
71	Clinical approach to diarrhea. <i>Internal and Emergency Medicine</i> , 2012, 7, 255-262.	1.0	34
72	Is gastroparesis a gastric disease?. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13562.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. <i>Nutrients</i> , 2020, 12, 3735.	1.7	34
74	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877130.	1.4	33
75	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. <i>Gut</i> , 2009, 58, 1571-1575.	6.1	32
76	Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons. <i>Pain</i> , 2018, 159, 1257-1267.	2.0	31
77	Mucosal Barrier Defects in Irritable Bowel Syndrome. Who Left the Door Open?. <i>American Journal of Gastroenterology</i> , 2006, 101, 1295-1298.	0.2	31
78	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	30
79	Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2017, 49, 595-603.	0.4	29
80	Probiotics in irritable bowel syndrome: Where are we?. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13513.	1.6	28
81	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. <i>Journal of Pediatrics</i> , 2018, 195, 128-133.e1.	0.9	26
82	Probiotics and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S214-S217.	1.1	25
83	μ-opioid receptor, δ -endorphin, and cannabinoid receptor are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13688.	1.6	25
84	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 741-749.	0.4	24
85	Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome. <i>Digestive Diseases</i> , 2009, 27, 115-121.	0.8	23
86	Evidence that tachykinins are the main NANC excitatory neurotransmitters in the guinea-pig common bile duct. <i>British Journal of Pharmacology</i> , 1998, 124, 1703-1711.	2.7	21
87	Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Controversial Issues. <i>Digestive Diseases</i> , 2007, 25, 245-248.	0.8	21
88	<i>Escherichia coli</i> Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13388.	1.6	21
89	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	1.6	21
90	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.5	21

#	ARTICLE	IF	CITATIONS
91	East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. <i>Gut</i> , 2004, 53, 1068-1069.	6.1	20
92	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 389-393.	1.5	19
93	Probiotics: could they turn out to be ineffective in irritable bowel syndrome?. <i>Digestive and Liver Disease</i> , 2000, 32, 302-304.	0.4	18
94	Treatment of Diverticular Disease With Aminosalicylates. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S60-S63.	1.1	18
95	Glioplasticity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13232.	1.6	17
96	Faecal microbial transplantation in IBS: ready for prime time?. <i>Gut</i> , 2020, 69, 795-796.	6.1	16
97	Curriculum for neurogastroenterology and motility training: A report from the joint <sc>ANMS</sc>â€œ<sc>ESNM</sc> task force. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13341.	1.6	15
98	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVIDâ€™19 pandemic. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13930.	1.6	15
99	Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6698.	1.8	15
100	Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry. <i>United European Gastroenterology Journal</i> , 2018, 6, 926-934.	1.6	14
101	Nerve fiber overgrowth in patients with symptomatic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13575.	1.6	14
102	An international survey on clinicians' perspectives on the diagnosis and management of chronic intestinal pseudoâ€œobstruction and enteric dysmotility. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13937.	1.6	14
103	Biomarkers for IBS: ready for prime time?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 9-10.	8.2	12
104	Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12928.	1.6	12
105	Serine proteases: new players in diarrhoea-predominant irritable bowel syndrome. <i>Gut</i> , 2008, 57, 1035-1037.	6.1	11
106	Diagnostic challenges of symptomatic uncomplicated diverticular disease. <i>Minerva Gastroenterology</i> , 2017, 63, 119-129.	0.3	11
107	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 735-740.	1.4	9
108	Toll-Like Receptor Expression in Irritable Bowel Syndrome: On the Alert for a Microbial Threat?. <i>American Journal of Gastroenterology</i> , 2011, 106, 337-339.	0.2	9

#	ARTICLE	IF	CITATIONS
109	Funding for gastrointestinal disease research in the European Union. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 593-595.	3.7	9
110	Habitual Green Kiwifruit Consumption Is Associated with a Reduction in Upper Gastrointestinal Symptoms: A Systematic Scoping Review. <i>Advances in Nutrition</i> , 2022, 13, 846-856.	2.9	9
111	Role of inflammation in pediatric irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14365.	1.6	7
112	What is the effect of inflammation on intestinal function?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S140-S144.	0.9	6
113	A New Reliable Method for Evaluating Gallbladder Dynamics. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 297-304.	0.8	6
114	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 251-263.	1.9	6
115	Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry. <i>United European Gastroenterology Journal</i> , 2019, 7, 815-824.	1.6	6
116	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. <i>Digestive and Liver Disease</i> , 2021, 53, 202-209.	0.4	5
117	475j Nerve Growth and Plasticity in the Colonic Mucosa of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2010, 138, S-65-S-65.	0.6	4
118	Gastrointestinal Bleeding In Covid-19 Patients: A Systematic Review And Meta-Analysis. <i>Endoscopy</i> , 2021, 53, .	1.0	4
119	Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double-blind study. <i>GastroHep</i> , 2020, 2, 295-308.	0.3	3
120	Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms. <i>Scientific Reports</i> , 2021, 11, 8077.	1.6	3
121	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-29.	0.5	3
122	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.5	2
123	Role of Smooth Muscle in Intestinal Inflammation. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1996, 10, 249-253.	1.8	1
124	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 11-16.	0.5	1
125	New perspectives in irritable bowel syndrome. <i>Digestive and Liver Disease</i> , 2009, 41, 843.	0.4	0
126	In memoriam of a master of neurogastroenterology: Marcello Tonini (1944-2010). <i>Neurogastroenterology and Motility</i> , 2010, 22, 942-943.	1.6	0

#	ARTICLE	IF	CITATIONS
127	The Brain-Gut Axis and the Gender. , 2019, , 245-253.		0
128	SeHCAT test for bile acid malabsorption: may it become the gold one in the diagnostic burden of chronic diarrhea?. Clinical and Translational Imaging, 2021, 9, 177-180.	1.1	0
129	Protease-Activated Receptor 1 is implicated in irritable bowel syndrome mediators-induced signalling to human sensory neurons. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR3-3.	0.0	0